Arpida AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private, Subsidiary
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.arpida.com
Clinical Trials
11
Active:8
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (50.0%)Phase 1
1 (25.0%)Phase 2
1 (25.0%)Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
Phase 2
Terminated
- Conditions
- Hospital-Acquired PneumoniaVentilator-Associated PneumoniaHealth-Care-Associated Pneumonia
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Arpida AG
- Target Recruit Count
- 135
- Registration Number
- NCT00543608
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
Phase 3
Completed
- Conditions
- Skin Diseases, Bacterial
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2007-03-27
- Lead Sponsor
- Arpida AG
- Registration Number
- NCT00303550
- Locations
- 🇺🇸
Edward Hospital & Health Services, Naperville, Illinois, United States
🇺🇸Wyoming Medical Center, Casper, Wyoming, United States
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)
Phase 3
Completed
- Conditions
- Complicated Skin and Skin Structure Infection
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Arpida AG
- Registration Number
- NCT00299520
- Locations
- 🇺🇸
e-Study Site, National City, California, United States
🇺🇸VA Medical Center, Boise, Idaho, United States
🇺🇸Infectious Disease of Indiana, Indianapolis, Indiana, United States
News
No news found